<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="60">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 03, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04325061</url>
  </required_header>
  <id_info>
    <org_study_id>2020-001278-31</org_study_id>
    <nct_id>NCT04325061</nct_id>
  </id_info>
  <brief_title>Efficacy of Dexamethasone Treatment for Patients With ARDS Caused by COVID-19</brief_title>
  <acronym>DEXA-COVID19</acronym>
  <official_title>Efficacy of Dexamethasone Treatment for Patients With ARDS Caused by COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Negrin University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Li Ka Shing Knowledge Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Consorcio Centro de Investigación Biomédica en Red, M.P.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dr. Negrin University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: There are no proven therapies specific for Covid-19. The full spectrum of
      Covid-19 ranges from asymptomatic disease to mild respiratory tract illness to severe
      pneumonia, acute respiratory distress syndrome (ARDS), multiorgan failure, and death. The
      efficacy of corticosteroids in viral ARDS remains controversial.

      Methods: This is an internationally (Spain, Canada, China, USA) designed multicenter,
      randomized, controlled, open-label clinical trial testing dexamethasone in mechanically
      ventilated adult patients with established moderate-to-severe ARDS caused by confirmed
      Covid-19 infection, admitted in a network of Spanish ICUs. Eligible patients will be randomly
      assigned to receive either dexamethasone plus standard intensive care, or standard intensive
      care alone. Patients in the dexamethasone group will receive an intravenous dose of 20 mg
      once daily from day 1 to day 5, followed by 10 mg once daily from day 6 to day 10. The
      primary outcome is 60-day mortality. The secondary outcome is the number of ventilator-free
      days at 28 days. All analyses will be done according to the intention-to-treat principle.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The acute respiratory distress syndrome (ARDS) is a catastrophic illness of multifactorial
      etiology characterized by a diffuse, severe inflammatory process of the lung leading to acute
      hypoxemic respiratory failure requiring mechanical ventilation (MV). Pulmonary infections are
      the leading causes of ARDS. Clinical and experimental research has established a strong
      association between dysregulated systemic and pulmonary inflammation and progression or
      delayed resolution of ARDS.

      The COVID-19 pandemic is a critical moment for the world. Severe pneumonia is the main
      condition leading to ARDS requiring weeks of MV with high mortality (40-60%) in COVID-19
      patients. There is no specific therapy for Covid-19, although patients are receiving drugs
      that are already approved for treating other diseases. There has been great interest in the
      role of corticosteroids to attenuate the pulmonary and systemic damage in ARDS patients
      because of their potent anti-inflammatory and antifibrotic properties. However, the efficacy
      of corticosteroids in viral ARDS remains controversial.

      We justify the need of this study based on the positive results of a recent clinical trial by
      our group, showing that dexamethasone for 10 days was able to reduce the duration of
      mechanical ventilation (MV) and increase hospital survival in patients with ARDS from
      multiple causes (Villar J et al. Lancet Respir Med 2020). Dexamethasone has never been
      evaluated in viral ARDS in a randomized controlled fashion. Our goal in this study is to
      examine the effects of dexamethasone on hospital mortality and on ventilator-free days in
      patients with moderate-to-severe ARDS due to confirmed COVID-19 infection admitted into a
      network of Spanish intensive care units (ICUs).
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2020</start_date>
  <completion_date type="Anticipated">October 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Multicenter, randomized, controlled, open-label trial involving mechanically ventilated adult patients with ARDS caused by confirmed COVID-19 infection</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>60-day mortality</measure>
    <time_frame>60 days</time_frame>
    <description>All-cause mortality at 60 days after enrollment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ventilator-free days</measure>
    <time_frame>28 days</time_frame>
    <description>Number of ventilator-free days (VFDs) at Day 28 (defined as days being alive and free from mechanical ventilation at day 28 after enrollment, For patients ventilated 28 days or longer and for subjects who die, VFD is 0.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Acute Respiratory Distress Syndrome Caused by COVID-19</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients will be treated with standard intensive care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexamethasone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard intensive care plus dexamethasone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Dexamethasone (20 mg/iv/daily/from Day 1 of randomization during 5 days, followed by 10 mg/iv/daily from Day 6 to 10 of randomization</description>
    <arm_group_label>Dexamethasone</arm_group_label>
    <other_name>dexamethasone Indukern</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 18 years or older;

          -  positive reverse-transcriptase-polymerase-chain-reaction (RT-PCR) assay for COVID-19
             in a respiratory tract sample;

          -  intubated and mechanically ventilated;

          -  acute onset of ARDS, as defined by Berlin criteria as moderate-to-severe ARDS,3 which
             includes: (i) having pneumonia or worsening respiratory symptoms, (ii) bilateral
             pulmonary infiltrates on chest imaging (x-ray or CT scan), (iii) absence of left
             atrial hypertension, pulmonary capillary wedge pressure &lt;18 mmHg, or no clinical signs
             of left heart failure, and (iv) hypoxemia, as defined by a PaO2/FiO2 ratio of ≤200
             mmHg on positive end-expiratory pressure (PEEP) of ≥5 cmH2O, regardless of FiO2.

        Exclusion Criteria:

          -  Patients with a known contraindication to corticosteroids,

          -  Decision by a physician that involvement in the trial is not in the patient's best
             interest,

          -  Pregnancy and breast-feeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jesús Villar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Dr. Negrin</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jesús Villar, MD</last_name>
    <phone>+34606860027</phone>
    <email>jesus.villar54@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Arthur Slutsky, MD</last_name>
    <phone>+14168244000</phone>
    <email>SLUTSKYA@smh.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Anesthesia, Hospital Universitario de Cruces</name>
      <address>
        <city>Barakaldo</city>
        <state>Vizcaya</state>
        <zip>48903</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Gonzalo Tamayo, MD, PhD</last_name>
      <phone>+34655740637</phone>
      <email>gonzalotamayo@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Alberto Martínez-Ruiz, MD, PhD</last_name>
      <phone>+34610494664</phone>
      <email>alberto.martinezruiz@osakidetza.net</email>
    </contact_backup>
    <investigator>
      <last_name>Iñaki Bilbao-Villasante</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Intensive Care Unit, Hospital Universitario de Cruces</name>
      <address>
        <city>Barakaldo</city>
        <state>Vizcaya</state>
        <zip>48903</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Tomás Muñoz, MD, PhD</last_name>
      <phone>+34619440485</phone>
      <email>tomas.munozmartinez@osakidetza.net</email>
    </contact>
    <contact_backup>
      <last_name>Pablo Serna-Grande, MD</last_name>
      <phone>+34620686825</phone>
      <email>pablo.serna.grande@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Department of Anesthesia, Hospital Clinic</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Carlos Ferrando, MD, PhD</last_name>
      <phone>+34659583815</phone>
      <email>cafeoranestesia@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Intensive Care Unit, Hospital General de Ciudad Real</name>
      <address>
        <city>Ciudad Real</city>
        <zip>13005</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Alfonso Ambrós, MD, PhD</last_name>
      <phone>+34696544641</phone>
      <email>alfonsoa@sescam.jccm.es</email>
    </contact>
    <contact_backup>
      <last_name>Carmen Martín, MD</last_name>
      <email>mcarmartin@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Rafael del Campo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Dr. Negrin</name>
      <address>
        <city>Las Palmas de Gran Canaria</city>
        <zip>35019</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Anesthesia, Hospital Universitario La Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Fernando Ramasco, MD, PhD</last_name>
      <phone>+34639667114</phone>
      <email>gorria66@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Intensive Care Unit, Hospital Universitario La Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Fernando Suarez-Sipmann, MD, PhD</last_name>
      <phone>+34669792961</phone>
      <email>fsuarezsipmann@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Intensive Care Unit, Hospital Universitario Fundación Jiménez Díaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>César Pérez-Calvo, MD</last_name>
      <phone>+34618100522</phone>
      <email>Cperez@fjd.es</email>
    </contact>
    <contact_backup>
      <last_name>Ánxela Vidal, MD</last_name>
      <phone>+34680713669</phone>
      <email>anxelavidal@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Department of Anesthesia, Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Emilio Maseda, MD, PhD</last_name>
      <email>emilio.maseda@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Intensive Care Unit, Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>José M Añón, MD, PhD</last_name>
      <phone>+34620152794</phone>
      <email>jmaelizalde@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Intensive Care Unit, Hospital Universitario Virgen de la Arrixaca</name>
      <address>
        <city>Murcia</city>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Domingo Martínez, MD</last_name>
      <phone>+34670334050</phone>
      <email>dmbct1@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Juan A Soler, MD, PhD</last_name>
      <phone>+34661764387</phone>
      <email>juasobar@hotmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Department of Anesthesia, Hospital Unversitario Montecelo</name>
      <address>
        <city>Pontevedra</city>
        <zip>36071</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Marina Varela, MD, PhD</last_name>
      <phone>+34607358008</phone>
      <email>marina.varela.duran@sergas.es</email>
    </contact>
    <contact_backup>
      <last_name>Pilar Diaz-Parada, MD</last_name>
      <phone>+34686101085</phone>
      <email>pilar.diaz.parada@sergas.es</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Department of Anesthesia, Hospital Clinico Universitario</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Gerardo Aguilar, MD, PhD</last_name>
      <phone>+34639715165</phone>
      <email>gaguilar.aguilar1@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>José A Carbonell, MD</last_name>
      <email>jsoeacarbonell19@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Intensive Care Unit, Hospital Clinico Universitario</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>José Ferreres, MD, PhD</last_name>
      <phone>+34627557288</phone>
      <email>ferreresj@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Intensive Care Unit, Hospital Universitario La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Álvaro Castellanos, MD, PhD</last_name>
      <phone>+34677984787</phone>
      <email>catellanos_alv@gva.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Anesthesia, Hospital Clínico Universitario</name>
      <address>
        <city>Valladolid</city>
        <zip>47003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>José I Gómez-Herreras, MD, PhD</last_name>
      <email>jgomez012001@yahoo.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Intensive Care Unit, Hospital Universitario Río Hortega</name>
      <address>
        <city>Valladolid</city>
        <zip>47012</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Lorena Fernández, MD, PhD</last_name>
      <phone>+34626479670</phone>
      <email>mlorefer@yahoo.es</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 25, 2020</study_first_submitted>
  <study_first_submitted_qc>March 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2020</study_first_posted>
  <last_update_submitted>March 31, 2020</last_update_submitted>
  <last_update_submitted_qc>March 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dr. Negrin University Hospital</investigator_affiliation>
    <investigator_full_name>Jesus Villar</investigator_full_name>
    <investigator_title>Senior scientist</investigator_title>
  </responsible_party>
  <keyword>ARDS</keyword>
  <keyword>COVID-19</keyword>
  <keyword>multiple system organ failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

